Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti‐seizure medication

OBJECTIVE: As of 2022, 36 anti‐seizure medications (ASMs) have been licensed for the treatment of epilepsy, however, adverse effects (AEs) are commonly reported. Therefore, ASMs with a wide margin between therapeutic effects and AEs are preferred over ASMs that are associated with a narrow margin be...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukushima, Kazuyuki, Higashiyama, Hiroyuki, Kazuta, Yuji, Hashimoto, Keisuke, Watanabe, Naoto, Furuya, Yoshiaki, Ito, Yoshimasa, Wu, Ting, Kosasa, Takashi, Talos, Delia M., Song, Yeri, Roberts, Nicholas S., Jensen, Frances E., Hanada, Takahisa, Ido, Katsutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472371/
https://www.ncbi.nlm.nih.gov/pubmed/37052238
http://dx.doi.org/10.1002/epi4.12741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472371/
https://www.ncbi.nlm.nih.gov/pubmed/37052238
http://dx.doi.org/10.1002/epi4.12741

Ejemplares similares